HEC68498

HEC68498 is an orally bioavailable small molecule inhibitor that targets class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR). It is being developed primarily for the treatment of idiopathic pulmonary fibrosis and solid tumors. The drug exhibits potential anti-fibrotic, anti-inflammatory, and antineoplastic activities by inhibiting key signaling pathways involved in cell proliferation and survival. Clinical development has included phase 1 trials in both idiopathic pulmonary fibrosis and oncology indications. The developer is HEC Pharm, with Sunshine Lake Pharma as a subsidiary involved in its development[1][2][4][7].

Other names

HEC68498 sodiumHEC-68498 sodiumHEC 68498 sodiummono-sodium salt of HEC-68498